FGF23

Most people never think about phosphate, but the hormone FGF23 (fibroblast growth factor 23) sits at the center of how your body handles it. The gene that codes for this hormone carries inherited variants that appear to shift how much of the hormone you make and how your kidneys, heart, and bones respond to it over a lifetime.

Looking at your FGF23 gene gives you a window into inherited tendencies for kidney and cardiovascular biology that standard panels do not capture. This is a research-grade genetic test rather than a routine clinical screening tool, so it works best as one piece of a longer-term picture of your kidney and heart biology.

What the FGF23 Gene Does

The FGF23 gene is the blueprint your body uses to make a hormone called fibroblast growth factor 23. This hormone is produced mostly by cells inside your bones, then released into the bloodstream where it tells your kidneys to do three things: dump more phosphate into urine, slow down activation of vitamin D, and adjust signals to the parathyroid glands. Together, these actions keep phosphate from building up in your blood.

Inherited differences in the FGF23 gene appear to change how much of this hormone you produce, how stable it is in circulation, and how your kidneys read its signal. Genome-wide studies in several thousand adults have identified specific spots in and around the FGF23 gene that explain part of the differences in circulating hormone levels between individuals. Some of these variants sit in regions tied to vitamin D processing and phosphate transport, which helps explain why two people on the same diet can show very different phosphate biology.

Kidney Disease Risk

One reason to look at the FGF23 gene comes from kidney research. In an observational study of 632 Mexican adults with type 2 diabetes or high blood pressure, specific haplotypes (combinations of variants) in the FGF23 gene were associated with chronic kidney disease (CKD) risk. The minor alleles of two FGF23 variants appeared protective against kidney disease in that cohort, meaning the relationship is not simply one direction. These findings come from a single population and have not yet been replicated broadly.

This matters because FGF23 hormone levels rise very early in CKD, often years before phosphate or parathyroid hormone start to drift. In the Chronic Renal Insufficiency Cohort study of 3,879 adults with CKD, elevated FGF23 was an early detectable signal of disordered phosphate metabolism. If you inherited variants that nudge your baseline FGF23 biology in an unfavorable direction, that early signal may show up sooner.

Cardiovascular Implications

FGF23 is not just a kidney hormone. Higher circulating levels have been linked to left ventricular hypertrophy (thickening of the heart's main pumping chamber), heart failure, atrial fibrillation, and worse outcomes after a heart attack. A study of more than 35,000 patients with atrial fibrillation found that higher FGF23 levels were associated with increased risk of all-cause and cardiovascular mortality, heart failure, and ischemic stroke. These findings come from hormone measurements, not from the gene test itself.

Whether variants in the FGF23 gene directly drive these cardiovascular outcomes is still being worked out. Genetic studies using inherited variants to predict FGF23 levels found a link to heart failure with preserved ejection fraction in people with lower genetically predicted kidney function, but no link in broader heart failure populations. The takeaway is that the gene appears to matter most when other risk factors are also in play.

Reconciling What the Gene Test and Hormone Test Tell You

A common point of confusion is that the FGF23 gene test and the FGF23 hormone blood test are not the same. The gene test reads your inherited DNA and reflects lifetime tendencies. The hormone test reads your current circulating level, which moves with kidney function, iron status, inflammation, and diet. Most of the published outcome data, including the large kidney and heart studies, comes from hormone measurements, not gene variants. Your DNA result is best understood as a backdrop that may help interpret hormone numbers, not a substitute for them.

Tracking Over Time

Your DNA does not change, so the FGF23 gene result itself is a one-time read. What changes is the context: your kidney function, blood pressure, phosphate and vitamin D status, and cardiovascular risk all evolve over the years. The value of knowing your genetic backdrop comes from pairing it with regular monitoring of those moving parts. A reasonable approach is to establish your gene result once, then track kidney markers (creatinine, cystatin C, eGFR), phosphate, and cardiac risk markers at least annually, more often if you are making lifestyle changes or have a family history of kidney or heart disease.

When Results Can Be Misleading

• Variant interpretation evolves: the meaning of a specific FGF23 variant can change as more population data accumulate. A variant labeled uncertain today may be reclassified later.
• Population differences: the kidney disease associations identified for FGF23 variants come from specific cohorts, including Mexican adults with diabetes and hypertension. Your individual risk depends on your ancestry, other genes, and lifestyle factors that the test does not measure.
• Single gene, multi-factor disease: even an unfavorable FGF23 genotype is one input among many. Kidney and cardiovascular outcomes also depend on common variants across many other genes, none of which this test captures.
• Not a diagnostic test: an at-risk genotype does not mean you have kidney disease or heart failure. It is a probability shift, not a diagnosis.

What to Do With an At-Risk Result

If your FGF23 gene result points toward a higher-risk pattern, the next steps are about adding context rather than panic. Pair the genetic finding with a current snapshot of kidney function (creatinine, cystatin C, eGFR, urine albumin-to-creatinine ratio), mineral metabolism (phosphate, calcium, vitamin D, parathyroid hormone), and cardiovascular risk (lipid panel, blood pressure, hs-CRP). If multiple findings line up in a concerning direction, that is the point to involve a nephrologist or preventive cardiologist who can build a long-term monitoring plan. An at-risk genotype with completely normal kidney and heart markers usually means watchful tracking, not immediate intervention.